Dr. Anna Nolan, MD

Media Releases

Combining Clinical Expertise with Innovative Research to Tackle Lung Disease and Improve Patient Outcomes

New York, New York – Anna Nolan, MD, a skilled pulmonologist and physician-scientist, proudly serves as the Director of Research Oversight at NYC Health + Hospitals / Bellevue, while also treating adults at NYU Langone Pulmonary And Critical Care Associates on 41st Street. With her extensive background in pulmonary and critical care medicine, Dr. Nolan is dedicated to advancing the field through both clinical practice and groundbreaking research.

As a Professor in the Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine at NYU Grossman School of Medicine, Dr. Nolan brings a wealth of knowledge and experience to her role. She earned her Bachelor of Arts Degree in Chemistry from Barnard College in 1992 and her Medical Degree from SUNY-Downstate’s College of Medicine in 1996. Following her internal medicine residency at St. Luke’s-Roosevelt Hospital Center, she completed a fellowship in pulmonary and critical care medicine at NYU Grossman School of Medicine in 2003 and obtained her Master of Science Degree in Clinical Investigation from the same institution in 2007.

Dr. Nolan is board-certified in internal medicine, pulmonary disease, and critical care medicine, with certifications dating back to 1999, 2002, and 2003, respectively. She is a Fellow of both the American College of Chest Physicians and the American Thoracic Society, as well as a member of the Society of Critical Care Medicine.

Currently, as Principal Investigator of the Nolan Lab at NYU Langone, Dr. Nolan leads a team focused on investigating the impact of World Trade Center dust exposure on lung function using mouse models. Her research also delves into the roles of the receptor for advanced glycation end products (RAGE) and lysophosphatidic acid (LPA), a cholesterol derivative, as part of her broader interests that include COVID-19, biomarkers, and lung inflammation. 

Dr. Nolan’s innovative approach incorporates machine learning and artificial intelligence to develop prediction models aimed at understanding metabolic syndrome, cardiovascular disease, and aerodigestive conditions. Her work is crucial in examining the impact of these conditions on lung health and overall disease progression.

Fluent in English and Greek, Dr. Nolan is committed to improving health outcomes for diverse communities in New York City. Her dedication to research and patient care continues to inspire fellow clinicians and researchers alike.

Recommended Articles

• Causes of Lung Nodules

  What are lung nodules?Lung nodules are spots present on the lung. These spots are usually around 1.5 inches or three centimeters in diameter. Lung nodules seen on imaging tests are often called as coin lesions. If a lung X-ray shows spots that are more than three centimeters, it is regarded as a...

• What #break40 Means to Patients Living with Cystic Fibrosis

  2-year-old James Alexander Cargal is a bubbly and energetic little boy who enjoys singing, dancing, and playing with his dogs. But he is also a fighter. James was diagnosed with cystic fibrosis at just three weeks old. CF is a genetic disease that mostly affects the lungs, triggering persistent lung...

• Antibiotics for Cystic Fibrosis

  Cystic fibrosis damages the lungs, digestive system, and other organs in the body. It affects the cells producing mucus, sweat, and digestive juices. It is caused due to defect in a gene. This gene changes a protein responsible for movement of salts in and out of cells. As a result, thick, sticky...

• What Is Bronkaid?

  Generic Name: Ephedrine and GuaifenesinBrand Name: Primatene Asthma, BronkaidIntroduction Bronkaid is known for treating the symptoms of asthma. It works by thinning the mucus, so it can be eliminated from the body through coughing. Bronkaid consists of two active ingredients:...

• New Lung Cell Type Discovered May Be a Key to Efforts to Cure CF

  After years and years of studying the CFTR (cystic fibrosis transmembrane conductance regulator) gene and progress in the treatment of cystic fibrosis, researchers still have not been able to find a cure for the disease. But now, based on the findings of two independent studies, they are moving one...

• Recent Study Evaluates Venous Blood Clot Risk in Children with Cystic Fibrosis

  Children with cystic fibrosis may be at risk of developing what's called a venous thromboembolism. This is essentially a blood clot that forms in the deep veins of the body, most often in the lower legs. These clots can be extremely dangerous because they can dislodge and travel to vital organs,...